

Valeria Cernaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9286538/publications.pdf>

Version: 2024-02-01

72
papers

1,262
citations

331670

21
h-index

414414

32
g-index

72
all docs

72
docs citations

72
times ranked

2223
citing authors

#	ARTICLE	IF	CITATIONS
1	Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients. <i>International Urology and Nephrology</i> , 2022, 54, 395-403.	1.4	16
2	Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 244.	2.4	3
3	Indole-3-acetic acid correlates with monocyte-to-high-density lipoprotein (HDL) ratio (MHR) in chronic kidney disease patients. <i>International Urology and Nephrology</i> , 2022, 54, 2355-2364.	1.4	2
4	Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 323-339.	3.1	4
5	MO217: Proteinuria/BMI Ratio in Primary Membranous Nephropathy as a Possible Predictive Factor of Therapeutic Efficacy. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
6	Maternal peripheral blood CD34+ cells for prediction of fetal kidney malformations: results from a case-control analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 1679-1682.	1.5	0
7	Kidney Biopsy in Type 2 Diabetic Patients: Critical Reflections on Present Indications and Diagnostic Alternatives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5425.	4.1	24
8	MO466A NOVEL PREDICTION MARKER OF 10-YEAR RISK AND LIFETIME RISK OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH CKD AND DIABETES MELLITUS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
9	Commonly used immunosuppressive drugs for kidney diseases and pregnancy: focus on open questions. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1-3.	3.1	3
10	Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 258-264.	0.9	7
11	Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 871-880.	2.0	4
12	Maternal and Fetal Outcomes of Pregnancy in Nephrotic Syndrome Due to Primary Glomerulonephritis. <i>Frontiers in Medicine</i> , 2020, 7, 563094.	2.6	10
13	Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. <i>Journal of Clinical Medicine</i> , 2020, 9, 1261.	2.4	5
14	Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. <i>Pharmacological Research</i> , 2020, 159, 105019.	7.1	11
15	Protective Role of Vitamin D in Renal Tubulopathies. <i>Metabolites</i> , 2020, 10, 115.	2.9	21
16	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>Journal of Nephrology</i> , 2020, 33, 417-430.	2.0	8
17	RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus. <i>International Urology and Nephrology</i> , 2020, 52, 1125-1133.	1.4	14
18	Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements. <i>Medicinal Research Reviews</i> , 2019, 39, 427-460.	10.5	24

#	ARTICLE	IF	CITATIONS
19	Stress-induced hashitoxicosis: case report and relative HLA serotype and genotype. <i>Revista Da Associaç�o M�dica Brasileira</i> , 2019, 65, 830-833.	0.7	4
20	Role of Vitamin D Status in Diabetic Patients with Renal Disease. <i>Medicina (Lithuania)</i> , 2019, 55, 273.	2.0	34
21	Marked improvement of thyroid function and autoimmunity by <i>Aloe barbadensis miller</i> juice in patients with subclinical hypothyroidism. <i>Journal of Clinical and Translational Endocrinology</i> , 2018, 11, 18-25.	1.4	9
22	Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study. <i>Journal of Nephrology</i> , 2018, 31, 429-433.	2.0	5
23	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. <i>Pharmacological Research</i> , 2018, 129, 274-294.	7.1	47
24	The Myth of Water and Salt: From Aquaretics to Tenapanor. , 2018, 28, 73-82.		8
25	Wernicke-Korsakoff Syndrome in End-Stage Renal Disease: A Case Report. <i>Therapeutic Apheresis and Dialysis</i> , 2018, 22, 676-679.	0.9	3
26	Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Population-Based Analysis. <i>Therapeutic Apheresis and Dialysis</i> , 2018, 22, 457-468.	0.9	6
27	Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement. <i>Current Medicinal Chemistry</i> , 2018, 25, 4545-4551.	2.4	6
28	Novel avenues for treating diabetic nephropathy: new investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 445-462.	4.1	24
29	Opposite actions of urotensin II and relaxin on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 1069-1071.	1.9	2
30	Beneficial effects of oral pure caffeine on oxidative stress. <i>Journal of Clinical and Translational Endocrinology</i> , 2017, 10, 22-27.	1.4	44
31	The relationship between coping, emotion regulation, and quality of life of patients on dialysis. <i>International Journal of Psychiatry in Medicine</i> , 2017, 52, 111-123.	1.8	27
32	Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for β -catenin and c-kit expression. <i>Journal of Nephrology</i> , 2017, 30, 385-391.	2.0	5
33	Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2283.	4.1	41
34	Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0178699.	2.5	87
35	Renal biopsy: Still a landmark for the nephrologist. <i>World Journal of Nephrology</i> , 2016, 5, 321.	2.0	37
36	MP55SALT WATER DISEQUILIBRIUM AND FLUID OVERLOAD IN HEMODYALYSES PATIENTS: A CENTRAL ROLE OF CORIN. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i525-i525.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease, 2016, 9, 11.	1.8	25
38	MP463FGF23 KINETICS AND REMOVAL ON HAEMODIAFILTRATION. Nephrology Dialysis Transplantation, 2016, 31, i495-i496.	0.7	0
39	Sclerostin levels in uremic patients: a link between bone and vascular disease. Renal Failure, 2016, 38, 759-764.	2.1	17
40	Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. Biomarkers, 2016, 21, 371-378.	1.9	18
41	Metformin-related lactic acidosis: is it a myth or an underestimated reality?. Renal Failure, 2016, 38, 1560-1565.	2.1	29
42	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. Journal of Clinical and Translational Endocrinology, 2016, 6, 8-14.	1.4	34
43	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2016, , 535-556.		0
44	Kidney-lung connections in acute and chronic diseases: current perspectives. Journal of Nephrology, 2016, 29, 341-348.	2.0	27
45	Kidney disease and psoriasis: novel evidences beyond old concepts. Clinical Rheumatology, 2016, 35, 297-302.	2.2	25
46	Salt water imbalance and fluid overload in hemodialysis patients: a pivotal role of corin. Clinical and Experimental Medicine, 2016, 16, 443-449.	3.6	6
47	Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease. Current Medicinal Chemistry, 2016, 23, 1698-1707.	2.4	7
48	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2016, , 205-227.		0
49	Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	22
50	Auxin induces cell proliferation in an experimental model of mammalian renal tubular epithelial cells. Renal Failure, 2015, 37, 911-913.	2.1	7
51	Semaphorin 3A serum levels are influenced by haemodialysis: What clinical significance?. Nephrology, 2015, 20, 236-242.	1.6	1
52	Nephro-oncology: a link in evolution. Renal Failure, 2015, 37, 1260-1266.	2.1	7
53	Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opinion on Biological Therapy, 2015, 15, 1119-1143.	3.1	16
54	Unexpected hypercalcemia in a diabetic patient with kidney disease. World Journal of Nephrology, 2015, 4, 438.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2015, , 1-24.		0
56	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2015, , 1-22.		0
57	Vascular access for hemodialysis: current perspectives. International Journal of Nephrology and Renovascular Disease, 2014, 7, 281.	1.8	209
58	Proteinuric effect of transcranial magnetic stimulation in healthy subjects and diabetic patients with Stage 3-4 CKD. Nephrology Dialysis Transplantation, 2014, 29, 573-579.	0.7	4
59	New therapeutic strategies under development to halt the progression of renal failure. Expert Opinion on Investigational Drugs, 2014, 23, 693-709.	4.1	18
60	Vitamin D and Anemia. , 2014, 24, 61-62.		18
61	Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. Medicinal Research Reviews, 2014, 34, 77-105.	10.5	46
62	The future of phosphate binders: a perspective on novel therapeutics. Expert Opinion on Investigational Drugs, 2014, 23, 1459-1463.	4.1	15
63	New Insights on the Role of Vitamin D in the Progression of Renal Damage. Kidney and Blood Pressure Research, 2013, 37, 667-678.	2.0	45
64	Modifications in relaxin's serum levels during acetate-free biofiltration (AFB): only a new biomarker?. Italian Journal of Anatomy and Embryology, 2013, 118, 98-9.	0.1	3
65	NGAL as an Early Biomarker of Kidney Disease in Joubert Syndrome: Three Brothers Compared. Renal Failure, 2012, 34, 495-498.	2.1	14
66	Apelin, Plasmatic Osmolality and Hypotension in Dialyzed Patients. Blood Purification, 2012, 33, 317-323.	1.8	20
67	Fibrosis, regeneration and cancer: what is the link?. Nephrology Dialysis Transplantation, 2012, 27, 21-27.	0.7	29
68	NGAL is a Precocious Marker of Therapeutic Response. Current Pharmaceutical Design, 2011, 17, 844-849.	1.9	15
69	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	3.4	0
70	Erythropoietin and the truths of science. Journal of Nephrology, 2011, 24, 564-568.	2.0	8
71	Regenerative Medicine: Does Erythropoietin have a Role?. Current Pharmaceutical Design, 2009, 15, 2026-2036.	1.9	17
72	Down with the Erythropoietin. Long Live the Erythropoietin !. Current Drug Targets, 2009, 10, 1028-1032.	2.1	12